Researchers estimate that AI could generate up to $100 billion annually across the healthcare sector by optimizing clinical trials, streamlining administrative processes, and improving diagnosis accuracy. Yet, despite the promise, scaling AI beyond pilot projects and into widespread adoption remains a significant challenge. From data silos and regulatory hurdles to integration with legacy systems and ethical concerns, the road to AI-driven transformation is complex. During the opening panel discussion key opinion leaders will discuss actionable solutions on how to move AI implementation from pilot projects to enterprise-wide implementation.

Key discussion points include:

• From Pilot to Scale: How to successfully transition AI projects from limited trials to full enterprise deployment.
• Overcoming Data Silos: Strategies for integrating AI across fragmented healthcare data ecosystems while ensuring security and compliance.
• Human + AI Collaboration: How to empower healthcare professionals with AI tools that enhance decision-making rather than replace human expertise

As AI continues to revolutionise healthcare, critical questions remain about its global impact, accessibility, and long-term market sustainability. Despite rapid advancements, no AI-discovered drug has yet passed Phase 3 clinical trials—how close are we to this breakthrough, and what challenges must be overcome?This closing panel brings together leading experts to explore the future of AI-driven therapeutics, the evolving biotech-pharma relationship, and strategies for ensuring equitable access to AI-powered healthcare innovations.

Key topics include:

• The Road to AI Drug Approval: What hurdles remain before AI-discovered drugs reach the market?

• Funding & Investment: How can we secure sustainable funding for AI-driven drug development?

• Bridging the Accessibility Gap: Ensuring AI-powered healthcare benefits reach global populations